Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3710 - Factors Predicting Worse Outcomes in Patients with N0 Lung Adenocarcinoma of 3cm or Smaller


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer


Jung-Jyh Hung


Annals of Oncology (2017) 28 (suppl_5): v453-v456. 10.1093/annonc/mdx381


J. Hung, W. Hsu

Author affiliations

  • Department Of Surgery, Taipei Veterans General Hospital, 11217 - Taipei/TW


Abstract 3710


The role of adjuvant chemotherapy for patients with stage I non-small cell lung cancer remains unknown. The prognostic value of histological subtypes in resected node-negative small-sized lung adenocarcinoma has not been widely investigated. This study investigated the prognostic factors in patients with node-negative lung adenocarcinoma of 3cm or smaller to find potential candidates for adjuvant chemotherapy.


A total of 746 patients with completely resected node-negative lung adenocarcinoma of 3cm or smaller were included in the study. Prognostic factors for overall survival or probability of freedom from recurrence (FFR) were investigated.


The 5-year overall survival and recurrence-free rates were 86.8% and 84.8%, respectively. During follow-up, 59 (7.9%) patients developed recurrence. Univariate analysis showed that micropapillary/solid predominant group had significantly lower probability of FFR (P = 0.001) in node-negative lung adenocarcinoma of 3cm or smaller. Older age (P = 0.007), greater tumor size (P = 0.006), and micropapillary/solid predominant group (P = 0.031) had significantly lower probability of FFR in multivariate analysis.


The new adenocarcinoma classification has significant impact on recurrence in node-negative lung adenocarcinoma of 3cm or smaller. Patients with micropapillary/solid predominant pattern have significant higher risk for recurrence.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.